Idiopathic CD4+ lymphocytopenia: natural history and prognostic factors

DI Zonios, J Falloon, JE Bennett… - Blood, The Journal …, 2008 - ashpublications.org
DI Zonios, J Falloon, JE Bennett, PA Shaw, D Chaitt, MW Baseler, JW Adelsberger…
Blood, The Journal of the American Society of Hematology, 2008ashpublications.org
Abstract Idiopathic CD4+ lymphocytopenia (ICL) is a rare non–HIV-related syndrome with
unclear natural history and prognosis. This prospective natural history cohort study
describes the clinical course, CD4 T lymphocyte kinetics, outcome, and prognostic factors of
ICL. Thirty-nine patients (17 men, 22 women) 25 to 85 years old with ICL were evaluated
between 1992 and 2006, and 36 were followed for a median of 49.5 months. Cryptococcal
and nontuberculous mycobacterial infections were the major presenting opportunistic …
Abstract
Idiopathic CD4+ lymphocytopenia (ICL) is a rare non–HIV-related syndrome with unclear natural history and prognosis. This prospective natural history cohort study describes the clinical course, CD4 T lymphocyte kinetics, outcome, and prognostic factors of ICL. Thirty-nine patients (17 men, 22 women) 25 to 85 years old with ICL were evaluated between 1992 and 2006, and 36 were followed for a median of 49.5 months. Cryptococcal and nontuberculous mycobacterial infections were the major presenting opportunistic infections. Seven patients presented with no infection. In 32, CD4 T-cell counts remained less than 300/mm3 throughout the study period and in 7 normalized after an average of 31 months. Overall, 15 (41.6%) developed an opportunistic infection in follow-up, 5 (13.8%) of which were “AIDS-defining clinical conditions,” and 4 (11.1%) developed autoimmune diseases. Seven patients died, 4 from ICL-related opportunistic infections, within 42 months after diagnosis. Immunologic analyses revealed increased activation and turnover in CD4 but not CD8 T lymphocytes. CD8 T lymphocytopenia (< 180/mm3) and the degree of CD4 T cell activation (measured by HLA-DR expression) at presentation were associated with adverse outcome (opportunistic infection-related death; P = .003 and .02, respectively). This trial is registered at http://clinicaltrials.gov as #NCT00001319.
ashpublications.org